United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil 16 mg - candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joi

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx) - candesartan cilexetil 4 mg - candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to <17 years of age, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx) - candesartan cilexetil 4 mg - candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to <17 years of age, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - candesartan cilexetil; hydrochlorothiazide - tablet - 16/12.5 milligram(s) - angiotensin ii antagonists and diuretics; candesartan and diuretics

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - hydrochlorothiazide, quantity: 25 mg; candesartan cilexetil, quantity: 32 mg - tablet, uncoated - excipient ingredients: iron oxide red; hyprolose; lactose monohydrate; propylene glycol; iron oxide yellow; aluminium magnesium silicate; magnesium stearate; carmellose calcium - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - candesartan cilexetil; hydrochlorothiazide - tablet - 8mg /12.5 milligram(s) - angiotensin ii antagonists and diuretics; candesartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - candesartan cilexetil; hydrochlorothiazide - tablet - 32 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; candesartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - candesartan cilexetil; hydrochlorothiazide - tablet - 16 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; candesartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - hydrochlorothiazide; candesartan cilexetil - tablet - 16/12.5 milligram(s) - angiotensin ii antagonists and diuretics; candesartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - candesartan cilexetil; hydrochlorothiazide - tablet - 16/12.5 milligram(s) - angiotensin ii antagonists and diuretics; candesartan and diuretics